In the first of a two segment Phase 2a trial, 64 patients were enrolled and randomised to receive three doses of ACH-1625 given once daily (200mg, 400mg or 800mg) or placebo with peginterferon alfa-2a and ribavirin, a current standard of care.
The patients were dosed for 4 weeks of therapy, which was then followed by standard of care for 44 weeks.
The study results showed that 75-81% of patients treated with ACH-1625 achieved rapid virologic response (RVR) with a promising safety and tolerability profile.
ACH-1625 is a HCV protease inhibitor designed and synthesized based on crystal structures of enzyme/inhibitor complex.
It is an open chain, non-covalent, reversible inhibitor of NS3 protease.
In preclinical studies, ACH-1625 demonstrated high potency, unique pharmacokinetic properties and an excellent safety profile at high drug exposures